Everyday, about one million new malware threats are released. Many of them will fall by the wayside without causing much damage. But some will leave a malicious mark in the memory of CIOs and CISOs everywhere. An example of such a cyberthreat is Proteus malware, a cousin to the well-known Andromeda botnet. Here’s what you need to know about this multi-functional menace: 1. It Steals Your Cryptocurrency According to Bleeping Computer, Proteus can mine for cryptocurrency using SHA256 miner, CPUMiner and ZCashMiner, all of which leverage the local PC’s GPU or CPU to steal Bitcoin, Litecoin, Zcash, and other forms of cryptocurrency. On the surface, theft of cryptocurrency may not seem like a big deal, but it really is.
An increasing number of banks are preemptively purchasing cryptocurrency so they can more quickly deal with ransomware mitigation. Thanks to Proteus, having cryptocurrency is just as much of a liability as not having it. It Turns Your Computer into a SOCKS proxy A socket secure (SOCKS) proxy acts as an intermediary that relays traffic between a server and a client for any type of network protocol. Proteus essentially enables your computer to do this, meaning that malicious traffic can pass freely through an infected system. In essence, Proteus transforms one of your business endpoints into an open door for cybercriminals.
And to that end, Proteus is able to download and execute other types of malware that can be used against a host. It Verifies Stolen Credentials Some cybersecurity experts contend that Proteus’ primary or at least most intriguing purpose is to test the validity of stolen login credentials. These are typically for e-commerce sites such as Amazon and streaming services like Netflix. In addition to allowing hackers create a “master list” of stolen login credentials by evaluating them for use, this makes it possible to extract personally identifiable information from working accounts.
It Logs Your Key Strokes Keyloggers are some of the most dangerous types of malware because their goal is the silent extraction of sensitive information that can then be used against a victim later on. This includes login credentials for accounts that may contain PII. In other words, Proteus can steal login credentials, verify them on a continuing basis, use them to extract PII and then if need be, route that PII to a remote client. In other words, it’s a data-stealing machine. It Can be Be Beaten This multi-faceted strain of malware, which the SecurityIntelligence blog refers to as “the jerk of all trades, master of none,” is impressive, but it’s hardly the most complex or dangerous strain of malware we’ve come up against. It’s really just a matter of knowing how to beat it. Today to learn more.
About Proteus Digital Health Armed with more than 300 issued patents and led by some of the brightest minds in technology, pharmaceuticals and healthcare, we’ve invented Digital Medicine, a new category that measures medication treatment effectiveness, helps physicians improve clinical outcomes and patients reach health goals. Together, with leading health systems and pharmaceutical companies, we’re bringing this new digital solution to healthcare providers, thereby increasing access to better insight, optimized therapies and lower costs. Andrew Thompson Co-Founder, CEO Andrew Thompson is co-founder, president and chief executive officer of Proteus Digital Health.
His vision for Digital Medicine is focused on expanding global access to care, dramatically increasing the value delivered by drugs and creating a sustainable model for innovation that leverages the cell phone in everyone’s pocket. Andrew serves on the World Economic Forum Technology Pioneers selection committee and h e is also a Co-Founder and Board member of Summit Schools, a leading Charter High School organization with a unique digital platform. Andrew is active in digital humanities innovation with Stanford University and Cambridge University and a Co-Founder of Parker Library Online – the leading destination for digital medieval studies. He holds masters degrees in Engineering (Cambridge), Education (Stanford) and Business (Stanford GSB) and has a successful 25 year track record starting and building technology based healthcare companies in Silicon Valley. George Savage, M.D. Co-Founder, Chief Medical Officer George Savage is chief medical officer and co-founder of Proteus Digital Health, and formerly the company’s vice president of research and development. He sees Digital Medicine as an invaluable collaboration platform for patient and physician, integrating information about a patient’s response to therapy directly into everyday healthcare.
George is focused on developing the clinical and economic evidence needed to secure global regulatory approvals and spur widespread adoption of Proteus’s ingestible sensor platform. He serves on the board of the California Life Sciences Association, the Boston University College of Engineering advisory council, and in 2016 was elected a Fellow of the American Institute for Medical and Biological Engineering. George holds a B.S.
In biomedical engineering from Boston University, an M.D. From Tufts University School of Medicine, and an M.B.A. From Stanford University Graduate School of Business. He completed postgraduate training in surgery at the University of Massachusetts and is licensed to practice medicine in California. George has a successful 27-year track record of starting and developing technology-based healthcare companies in Silicon Valley. Mark Zdeblick, Ph.D.
Co-Founder, Chief Technologist Mark Zdeblick is chief technologist and co-founder of Proteus Digital Health, and leads the group innovating on our technology. Previously, Mark served as the chief technology officer for the optical switch group at K2 Optronics and served as founder and chief technology officer of Redwood Microsystems. Mark holds a B.S.
In civil engineering and a B.A. In architecture, both from the University of Illinois, and an M.S.
In aeronautics and astronautics and Ph.D. In electrical engineering from Stanford University. Uneek Mehra Chief Financial Officer As Chief Financial Officer, Uneek is responsible for accounting, financial reporting, budgeting, business planning and forecasting.
He is also responsible for the Facilities, IT and People teams. Prior to joining Proteus, Uneek had extensive experience in senior finance leadership roles with Novartis, IBM and Citibank. At Novartis, Uneek worked in roles with increasing responsibilities in the Corporate Finance, Commercial Finance, Corporate Business Development and Treasury departments across the US, Switzerland and China. He also served as CFO of two of the largest specialty Medicines Franchises within the Novartis US business. Uneek has a MBA in strategy and leadership from IMD, Lausanne, Switzerland as well as a Masters in Finance and a Bachelors in Engineering from premier universities in India.
Molly O'Neill Chief Commercial Officer Molly O’Neill is chief commercial officer of Proteus Digital Health, where she leads partnerships with major health systems, payers and key provider customers. Molly is a healthcare industry veteran with a 30+ year track record of developing and executing growth strategies to increase market share and revenues. Prior to joining Proteus, she was the Senior Vice President of business development at Tenet Healthcare, a diversified healthcare services company. Molly has also held leadership roles at Duke Medicine, Partners Healthcare, Inova Health System, Ascension Health Care Network, a joint venture between Ascension Health Alliance and Oak Hill Capital Partners. Having worked across major provider and healthcare service companies, Molly believes the greatest potential of Digital Medicines is in transforming a patient’s engagement with their physicians, their families and most importantly their own health. Molly is a member of the board of World Care International Inc.
And holds degrees from the Medical College of Virginia and Virginia Commonwealth University. David O'Reilly Chief Platform Officer David O’Reilly is chief platform officer of Proteus Digital Health and leads the company’s Digital Medicine development, manufacturing, corporate development and corporate strategy areas.
Prior to joining Proteus, David spent over 15 years starting and building life sciences companies focused on novel platforms for drug discovery and personalized medicine. He was President of Catalyst Biosciences, Chief Business Officer and member of the founding management team at Iconix Biosciences, and Head of Corporate Development for ARIAD Pharmaceuticals (where he was also the general manager of a subsidiary company, ARIAD Gene Therapeutics). He began his career as a management consultant to health care and biotechnology companies at L.E.K. Managing and leading others. David is a graduate of Wesleyan University, where he was named the Gilbert Clee Scholar, and Harvard Business School, where he received an MBA with Distinction.
Sean Handel Senior Vice President Product Sean Handel leads product management, design and software engineering at Proteus Digital Health. Most recently, Sean was Senior Vice President of Product at Swrve, a mobile engagement platform that helps major brands to engage their customers via their mobile apps. Previously, Sean was SVP Product Management and Marketing at Epocrates where he lead product initiatives from an early stage through the company’s IPO and subsequent acquisition by athenahealth.
This included offerings for providers, health systems, health plans, and pharmaceutical companies. Epocrates became the number one brand in healthcare technology for physicians—at its peak, Epocrates was used by more than 50% of all physicians in the US and 1.4 million healthcare providers overall. Sean holds Bachelor of Arts and Master of Science degrees in Computer Science from Northwestern University. He also advises technology startups in the healthcare technology and sports & fitness wearables areas. Neela Paykel Head of Legal Affairs and Compliance Neela Paykel is head of legal affairs and compliance at Proteus Digital Health. Prior to joining Proteus, Neela was assistant general counsel and practice group leader at Genentech where she served as the lead attorney providing legal support to the managed markets business unit. She advised on a broad range of managed care, healthcare law, privacy, antitrust and FDA promotional issues.
Prior to Genentech, Neela was at CVS Caremark serving as the lead counsel for health plan PBM business and was an Associate Counsel at Blue Shield. Neela is a graduate of Wesleyan University with a Bachelor of Arts in International Business Administration and received her Juris Doctorate degree from George Washington University. Jonathan Symonds, CBE Chairman Jon Symonds, CBE, is Chairman of HSBC Bank Plc, Chairman of the Supervisory Board of Innocoll AG and Non-executive Director of Genomics England. Formerly, Symonds was Chief Financial Officer of Novartis, Partner and Managing Director of Goldman Sachs and Chief Financial Officer of AstraZeneca Plc. Symonds has served on the Proteus Board of Directors since June of 2014 and now advises Proteus on strategy, financial management and corporate governance in his role as Chairman. Shumeet Banerji, Ph.D. Board Member Shumeet Banerji is founder and partner of Condorcet, LP an investment and advisory firm.
In 2013, Banerji retired from Booz & Company Inc. Having served as its founding Chief Executive Officer.
Formerly, he held leadership roles at Booz, Allen & Hamilton in India, the U.K., Europe and globally, where he advised public and private sector entities at the Board level. He serves on the Board of HP, Inc. And Innocoll, AG. Banerji provides oversight on Proteus’ corporate strategy and operational performance, among other topics of critical importance.
Work for a leader that's transforming the industry. We are Proteus Digital Health, the driving force behind an entirely new category of therapy called Digital Medicine. Every day, our employees are blazing new trails at the intersection of pharmaceuticals, technology, software and healthcare. Our company is on the forefront of transformative change to the healthcare industry. We are searching for pioneers, problem-solvers and inquisitive minds to help realize our vision: to improve healthcare for everyone, everywhere.
Do you want to work in a dynamic environment where you can grow personally as well as professionally? Then apply today to join the Proteus team. 'We are developing a product that is changing people's lives.' Laura Williams, Product Manager.
At Proteus Digital Health, we are developing leading-edge technology that will revolutionize how healthcare is delivered. What does that mean for our associates? They are playing an active role in the evolution of modern healthcare.
Whether you are a software engineer, a data analyst or a pharmaceutical expert, you can help develop and deliver solutions that enhance the quality of care for everyone:. Patients get back on track. Physicians get deeper insight into patient health. Healthcare systems can better measure, manage and improve the health of entire patient populations.
“We acknowledge hard work and celebrate success every chance we get.” Priya Raval, Senior Designer, HFE and User Research. Proteus Digital Health is a company like no other, offering the discipline of a healthcare leader and the mentality of a tech innovator. Every week, our associates are taking on challenges and solving problems. As a company on the leading edge, we’re searching for a unique type of employee — someone with an entrepreneurial mindset and a can-do spirit who enjoys working in a fast-paced environment. We offer:. Personal development — there’s always an opportunity to learn and grow. Entrepreneurial spirit — as an industry pioneer, we are constantly paving new ground.
Team mentality — we promote a culture of collaboration and teamwork. Dynamic working environment — every day is filled with new challenges and breakthroughs. Otsuka Otsuka and Proteus have combined Otsuka’s ABILIFY ® (aripiprazole) with the FDA-cleared Proteus ® ingestible sensor, embedding the sensor in single tablets at point of manufacture. The FDA granted its first approval of a Digital Medicine, ABILIFY MYCITE ® (aripiprazole tablets with sensor), on November 13, 2017. ABILIFY MYCITE ® is a drug -device combination product of Otsuka’s aripiprazole, an atypical antipsychotic, embedded with Proteus’ ingestible sensor that communicates with Proteus’ wearable sensor patch, and a smartphone application.
The product measures ingestion of ABILIFY MYCITE ® and patient activity, rest and mood. Otsuka’s first Digital Medicine provides an objective measure of medication-taking patterns of ABILIFY MYCITE ® to help enhance collaboration with healthcare providers, who treat patients with certain serious mental illnesses.